Fig 1.
Flow of participants through the SafeBoosC II study.
Table 1.
Baseline characteristics and treatment during the first 72 hours of life according to burden of cerebral hypo- or hyperoxia split in the three lowest quartiles and the highest quartile.
Fig 2.
Risk for adverse outcomes for infants with a burden of cerebral hypoxia within or below the 4th quartile.
Odds ratio (OR) and 95% confidence interval.
Fig 3.
Risk for adverse outcomes for infants with a burden of cerebral hyperoxia within or below the 4th quartile.
Odds ratio (OR) and 95% confidence interval.
Table 2.
Distributions of early and late adverse outcomes of cranial ultrasound, EEG variables, blood biomarkers, term diagnoses, and death according to the burden of cerebral hypoxia within or below the 4th quartile.
Table 3.
Distributions of early and late adverse outcomes of cranial ultrasound, EEG variables, blood biomarkers, term diagnoses, and death according to the burden of cerebral hyperoxia within or below the 4th quartile.